Engineering of tumour cells with cytokine genes to enhance their immunogenicity has been the subject of extensive investigation in recent years Schmidt-Wolf and Schmidt-Wolf, 1995) . Murine models have shown that transplantable tumour cells genetically engineered to produce cytokines are rejected by the syngeneic immunocompetent host. Some of these cytokines, such as IL-2 (Gansbacher et al., 1990; Fearon et al., 1990; Cavallo et al., 1992) , IL-4, IL-7 and interferon (IFN)-gamma (Allione et al., 1994; Colombo and Forni, 1994; Rosenthal et al., 1994) confer resistance to the subsequent injection of wild-type tumour cells by the induction of T-cell-mediated systemic immunity. These studies have provided the basis for the development of similar strategies of 'vaccination' with genetically modified tumour cells in humans (Schmidt-Wolf and Schmidt-Wolf, 1995) .
Among the various cytokines, IL-2 is one of the most commonly used in these studies. IL-2 mediates its stimulatory effects on T cells via a specific high-affinity receptor that is composed of at least three different chains involved in IL-2 binding, termed IL-2R a (CD25, p55 or TAC antigen), ,B (p75) and y (Taniguchi and Minamy, 1993) . In addition, a functional IL-2R molecule, displaying lower affinity, composed of IL-2R # and y chains, is constitutively expressed on natural killer (NK) cells and on some T cell subsets (Voss et al., 1992) . Expression of IL-2R chains has been reported not only on lymphoid cells but also on different human tumours, including squamous carcinoma (Weidmann et al., 1992; Yasumura et al., 1994) , melanoma Rimoldi et al., 1993) and others (McMillan et al., 1995) . On these tumour cells the IL-2R was shown to be functional: IL-2 may regulate expression of certain surface molecules such as ICAM-1, HLA class I and class II, and CD44 (Plaisance et al., 1993) and induce changes in the proliferative status of the tumour (Yasumura et al., 1994) .
Despite high sensitivity to chemotherapy and radiotherapy, small-cell lung cancer (SCLC), which accounts for 18% of primary lung cancers, still represents, in most cases, an incurable disease (Ihde, 1995) . A clinical study suggested a possible efficacy of exogenous IL-2 in SCLC (Clamon et al., 1993) and therapeutic approaches based on genetic engineering of SCLC with the IL-2 gene have been proposed (Cassileth, 1995 Morphological and immunohistochemical analysis of xenografts Groups of three mice were euthanised 2, 4 and 7 days after challenge. For histological evaluation, tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 4 gm and stained with haematoxylin and eosin or Giemsa.
For immunohistochemistry, acetone-fixed cryostat sections were incubated for 30 min with anti-L3T4 (CD4), anti-Lyt-2 (CD8a), anti-macrophage (M1/70.15) rat monoclonal antibody (MAb) (Sera-Lab, Crawley Down, Sussex, UK), anti-MAC-1 (CDl lb/CD18), anti-MAC-3, anti-Ia MAb (Boehringer Mannheim Corp., Milan, Italy), anti-granulocyte mAb (RB6-85C hybridoma provided by Dr RL Coffman, DNAX Inc., Palo Alto, CA, USA), anti-endothelial cell (MEC 13.3) (Vecchi et al., 1994) Characterisation of stable transfvectats of SCLC cell line.s e.xrp7essing the IL-2 genie The SCLC cell lines N592, NCI H69, NCI H 146, NCI H446 and IST-SLI were transfected with RSV.5 neo, L-2 vector by the use of cationic liposomes or by electroporation. Stable transfectants, surviving to G418 selection, expressed IL-2 transcripts, which were absent in untransfected cells ( Figure  2 ). As shown in Table II The N592 tumour model was also used to investigate the possible 'bystander' effects of the IL-2 secreted by transfected cells on the growth of simultaneously injected wild-type tumour cells. As shown in Figure 3b and c, the subcutaneous (Figure 4b ) and on day 7 the tumour growth area was replaced by a loose stromal tissue. Immunohistochemical observation revealed the presence of several granulocytes and macrophages (Figure 5a* and b*). These cells were scattered among the tumour cells or inside and at the edges of the necrotic areas. Asialo GM1+ cells were scarcely represented. The anti-endothelial cell MAb showed that the necrotic areas of IL-2-transfected N592 cell tumour were associated with a reduction of the tumour blood vessels (Figure 5c*) .
Discussion
In this study we show that SCLC cell lines do not display detectable surface IL-2 receptors and that expression of IL-2 gene by transfection does not significantly modify their in vitro biological characteristics. More importantly, IL-2 gene transfection abrogated the tumorigenic potential of SCLC cells in nude mice, possibly via activation of non-specific effector cell mechanisms. In addition, IL-2-transfected cells exerted a local 'bystander' effect on the growth of wild-type tumour cells.
Previous studies showed that functional IL-2 receptor molecules are present on some tumours and that IL-2 was able to modify the tumour proliferative behaviour or the expression of surface molecules relevant for the host-tumour interaction Yasumura et al., 1994; McMillan et al., 1995) . Our data indicate that in contrast to the above tumours, SCLC cell lines do not express detectable surface IL-2 receptor ox and chains, and that most of them also lack expression of IL-2R ,B and y chain mRNA. The latter finding is particularly important, since IL-2R y chain has been The finding that IL-2R is undetectable on SCLC is consistent with the lack of in vitro biological effects of IL-2 gene expression in five SCLC lines which were stably transfected with RSV.5 neo/IL-2. Hence, no effects on the in vitro cell growth rate, on the surface expression of HLA, CD44, ICAM-1, IL-2 R a and f molecules and of IL-2R ,B and y mRNA were detected. These findings also indicate that the loss of tumorigenicity of IL-2-tranfected tumour cells injected into nude mice, as well as the bystander effect, is not related to an autocrine effect of secreted IL-2 on SCLC cells, but to the in vivo activation of host effector mechanisms.
The study of reactive cells infiltrating the IL-2-transfected tumour during the rejection phase indicated that the effector cells involved were mainly represented by macrophages and granulocytes, while NK cells were scarcely represented. In this context, IL-2 receptors have been described on macrophages and IL-2 has been shown to act directly on murine macrophages by enhancing their cytolytic properties (Verstowsek et al., 1992) . A similar involvement of macrophages and neutrophils was previously reported in the rejection phase of murine IL-2-engineered tumour cells by the syngenic immunocompetent host (Cavallo et al., 1992) . In these previous studies the presence of a massive infiltrate of neutrophils and macrophages has been attributed to the secretion of inflammatory and chemotactic cytokines by infiltrating tumour-specific T lymphocytes (Colombo et al., 1992) . However, in the nude mice rejection model described herein, virtually no infiltrating T lymphocytes could be detected during rejection. This seemed to rule out the possibility of an involvement of residual T cell immunity in the nude mice. Similar findings were recently reported by Hara et al. (1995) : murine melanoma cells transduced with IL-2 were rejected in nude mice through an involvement of macrophages without T and NK cells.
Another possibility to be considered is related to a 'capillary leak' induced by IL-2 secreted by the tumour cells, which may alter the permeability of the vascularisation of the growing tumour. Indeed, it has been shown that endothelial cells express a functional IL-2R (Hicks et al., 1991) and that IL-2 activates arachidonic acid metabolism, influencing therefore the vascular permeability (Frazier-Scott et al., 1988) . In this context, the reduced presence of endothelial cells in xenografted transfectants is of note suggesting a vascular damage directly or indirectly related to IL-2. One may speculate that these alterations may allow, in the early phases of the rejection process, an increased extravasation of macrophages. These cells may be activated The finding that IL-2-transfected cells exert local but not systemic 'bystander' effects on the growth of wild-type tumour cells, may also be related to the fact that only low levels of human IL-2 (<2.5 U ml-1 by ELISA) could be achieved in the serum within the first 2-3 days after injection of transfected cells, while undetectable levels were found after 1 week. Thus, IL-2 secreted by tumour cells may act only locally on endothelial cells or on macrophages, while for the induction of a systemic immunity specific T cell responses are known to be required.
A models (Abdel-Wahab et al.. 1994 Ferrini et al.. 1987 ). In conclusion. our present data indicate that SCLC cells engineered to produce IL-2 are able to induce activation of non-specific effector cell mechanisms in vivo leading to tumour rejection. Further studies will be required to assess the possibility of inducing a systemic immunity in humans by engineering SCLC cells with multiple cytokines.
